A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Olaratumab (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Biomarker; Pharmacodynamics
- Sponsors Eli Lilly
- 21 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 21 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
- 10 Jun 2017 Biomarkers information updated